High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer

Experimental and Therapeutic Medicine

Volumn 5, Issue 1, 2013, Pages 102-106

  Jacobsen, Frank ^a   Ashtiani, Sharad Nouraie ^a   Tennstedt, Pierre ^a   Heinzer, Hans ^a   Simon, Ronald ^a   Sauter, Guido ^a   HÜSEYIN, Sirma ^a   Maria, Christina Tsourlakis ^a   Minner, Sarah ^a   Schlomm, Thorsten ^a   Michl, Uwe ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

C MET; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CELL LEVEL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 84869478137     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.764     Document Type: Article

References (25)

1. Cooper CS, Park M, Blair DG, et al: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311: 29-33, 1984.
2. Knudsen BS and Edlund M: Prostate cancer and the met hepa-tocyte growth factor receptor. Adv Cancer Res 91: 31-67, 2004.
3. Peruzzi B and Bottaro DP: Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12: 3657-3660, 2006.
4. Kong DS, Song SY, Kim DH, et al: Prognostic signifcance of c-Met expression in glioblastomas. Cancer 115: 140-148, 2009.
5. Lee YJ, Kim DH, Lee SH, Kim DW, Nam HS and Cho MK: Expression of the c-Met proteins in palignant skin cancers. Ann Dermatol 23: 33-38, 2011.
6. De Oliveira AT, Matos D, Logullo AF, et al: MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 29: 4807-4811, 2009.
7. Matteucci E, Bendinelli P and Desiderio MA: Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 30: 937-945, 2009.
8. Ichimura E, Maeshima A, Nakajima T and Nakamura T: Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic signifcance. Jpn J Cancer Res 87: 1063-1069, 1996.
9. Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y and Tahara E: Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer 55: 72-75, 1993.
10. Belfiore A, Gangemi P, Costantino A, et al: Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab 82: 2322-2328, 1997.
11. Humphrey PA, Zhu X, Zarnegar R, et al: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147: 386-396, 1995.
12. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925, 2003.
13. Knudsen BS, Gmyrek GA, Inra J, et al: High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60: 1113-1117, 2002.
14. Watanabe M, Fukutome K, Kato H, et al: Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett 141: 173-178, 1999.
15. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC and Chung LW: c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154: 293-298, 1995.
16. Tu WH, Zhu C, Clark C, Christensen JG and Sun Z: Effcacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 10: 556, 2010.
17. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ and Gallick GE: The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 20: 1677-1684, 2011.
18. Gross ME, Jo S and Agus DB: Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol 2: 53-56, 64, 2004.
19. Erbersdobler A, Fritz H, Schnöger S, et al: Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol 41: 40-46, 2002.
20. Bubendorf L: High-throughput microarray technologies: from genomics to clinics. Eur Urol 40: 231-238, 2001.
21. Miyamoto M, Ojima H, Iwasaki M, et al: Prognostic signifcance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer 105: 131-138, 2011.
22. Amemiya H, Menolascino F and Peña A: Role of the expression of c-Met receptor in the progression of gastric cancer. Invest Clin 51: 369-380, 2010 (In Spanish).
23. Freudlsperger C, Alexander D, Reinert S and Hoffmann J: Prognostic value of c-Met expression in oral squamous cell carcinoma. Exp Ther Med 1: 69-72, 2010.
24. Previdi S, Abbadessa G, Dalò F, France DS and Broggini M: Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther 11: 214-223, 2012.
25. Liu X, Wang Q, Yang G, et al: A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res 17: 7127-7138, 2011.